nach oben

Die Urologie

Erschienen in:

24.05.2017 | Schmerzsyndrome | CME

Interstitielle Zystitis

Diagnostik, medikamentöse und operative Therapie

verfasst von: Dr. A. Gonsior, J. Neuhaus, L. C. Horn, Prof. T. Bschleipfer, J.-U. Stolzenburg

Erschienen in: Die Urologie | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die interstitielle Zystitis/das Blasenschmerzsyndrom (IC/BPS) ist eine chronische Erkrankung mit weitreichenden negativen Auswirkungen auf die Lebensqualität. Eine autoimmungenetische Prädisposition korreliert mit der Theorie der Pathogenese. Die Diagnostik erfordert eine Anamnese, Miktionstagebücher, körperliche und differenzialdiagnostische Untersuchungen, eine Zystoskopie mit oder ohne Hydrodistension und/oder eine Blasenbiopsie. Verschiedene biologische Marker werden getestet, sind aber bisher nicht etabliert. Verhaltensmaßnahmen sowie pharmakologische orale und intravesikale, interventionelle und chirurgische Therapien mit einem breiten Spektrum publizierter Therapieerfolge stehen zur Verfügung. Ein multimodaler Ansatz ist empfehlenswert, den meisten therapeutischen Optionen fehlt es jedoch am „level of evidence“.

Hatchett L, Fitzgerald MP, Potts J et al (2009) Life impact of urologic pain syndromes. J Health Psychol 14(6):741–750CrossRefPubMedPubMedCentral

Jocham D, Froehlich G, Sandig F et al (2013) The care situation of patients with interstitial cystitis in Germany: results of a survey of 270 patients (Die Versorgungssituation von Patienten mit interstitieller Zystitis in Deutschland : Ergebnisse einer Umfrage unter 270 Betroffenen). Urologe A 52(5):691–702CrossRefPubMed

Hanno PM, Burks DA, Clemens JQ et al (2011) AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol 185(6):2162–2170CrossRefPubMed

Homma Y, Ueda T, Tomoe H et al (2016) Clinical guidelines for interstitial cystitis and hypersensitive bladder updated in 2015. Int J Urol 23(7):542–549CrossRefPubMed

Engeler DS, Baranowski AP, Dinis-Oliveira P et al (2013) The 2013 EAU guidelines on chronic pelvic pain: is management of chronic pelvic pain a habit, a philosophy, or a science? 10 years of development. Eur Urol 64(3):431–439CrossRefPubMed

Fall M, Baranowski AP, Elneil S et al (2010) EAU guidelines on chronic pelvic pain. Eur Urol 57(1):35–48CrossRefPubMed

van de Merwe JP, Nordling J, Bouchelouche P et al (2008) Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol 53(1):60–67CrossRefPubMed

Bschleipfer T, Vahlensieck W, Doggweiler R (2015) Interstitielle Zystitis/Blasenschmerzsyndrom. Urol Scan 02(04):265–278CrossRef

Parsons CL (2015) How does interstitial cystitis begin? Transl Androl Urol 4(6):605–610PubMedPubMedCentral

10.

Farmer MA, Chanda ML, Parks EL et al (2011) Brain functional and anatomical changes in chronic prostatitis/chronic pelvic pain syndrome. J Urol 186(1):117–124CrossRefPubMedPubMedCentral

11.

Clemens JQ, Meenan RT, Rosetti MCO et al (2005) Prevalence and incidence of interstitial cystitis in a managed care population. J Urol 173(1):98–102CrossRefPubMed

12.

Curhan GC, Speizer FE, Hunter DJ et al (1999) Epidemiology of interstitial cystitis: a population based study. J Urol 161(2):549–552CrossRefPubMed

13.

Kusek JW, Nyberg LM (2001) The epidemiology of interstitial cystitis: is it time to expand our definition? Urology 57(6 Suppl 1):95–99CrossRefPubMed

14.

Rosenberg MT, Page S, Hazzard MA (2007) Prevalence of interstitial cystitis in a primary care setting. Urology 69(4 Suppl):48–52CrossRefPubMed

15.

Berry SH, Elliott MN, Suttorp M et al (2011) Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol 186(2):540–544CrossRefPubMedPubMedCentral

16.

Hunner GL (1918) A rare type of bladder ulcer: further notes, with a report of eighteen cases. JAMA 17(70):203–212CrossRef

17.

Kuo HC (2014) Potential urine and serum biomarkers for patients with bladder pain syndrome/interstitial cystitis. Int J Urol 21(Suppl 1):34–41CrossRefPubMed

18.

Theoharides TC, Alysandratos K‑D, Angelidou A et al (2012) Mast cells and inflammation. Biochim Biophys Acta 1822(1):21–33CrossRefPubMed

19.

Altman D, Lundholm C, Milsom I et al (2011) The genetic and environmental contribution to the occurrence of bladder pain syndrome: an empirical approach in a nationwide population sample. Eur Urol 59(2):280–285CrossRefPubMed

20.

Emmungil H, Kalfa M, Zihni FY et al (2012) Interstitial cystitis: a rare manifestation of primary Sjogren’s syndrome, successfully treated with low dose cyclosporine. Rheumatol Int 32(5):1215–1218CrossRefPubMed

21.

Schwalenberg T, Berger FP, Horn LC et al (2015) Intravesical glycosaminoglycan replacement with chondroitin sulphate (Gepan((R)) instill) in patients with chronic radiotherapy- or chemotherapy-associated cystitis. Clin Drug Investig 35(8):505–512CrossRefPubMedPubMedCentral

22.

Warren JW, Jackson TL, Langenberg P et al (2004) Prevalence of interstitial cystitis in first-degree relatives of patients with interstitial cystitis. Urology 63(1):17–21CrossRefPubMed

23.

Davis NF, Brady CM, Creagh T (2014) Interstitial cystitis/painful bladder syndrome: epidemiology, pathophysiology and evidence-based treatment options. Eur J Obstet Gynecol Reprod Biol 175:30–37CrossRefPubMed

24.

NIDDK. https://www.niddk.nih.gov/health-information/health-topics/urologic-disease/interstitial-cystitis-painful-bladder-syndrome/Pages/facts.aspx. Accessed 24 Oct 2016

25.

Chambers GK, Fenster HN, Cripps S et al (1999) An assessment of the use of intravesical potassium in the diagnosis of interstitial cystitis. J Urol 162(3 Pt 1):699–701CrossRefPubMed

26.

Jiang Y‑H, Jhang J‑F, Kuo H‑C (2016) Revisiting the role of potassium sensitivity testing and cystoscopic hydrodistention for the diagnosis of interstitial cystitis. PLOS ONE 11(3):e0151692CrossRefPubMedPubMedCentral

27.

Keay SK, Zhang CO, Shoenfelt J et al (2001) Sensitivity and specificity of antiproliferative factor, heparin-binding epidermal growth factor-like growth factor, and epidermal growth factor as urine markers for interstitial cystitis. Urology 57(6 Suppl 1):9–14CrossRefPubMed

28.

Baka S, Kouskouni E, Antonopoulou S et al (2009) Prevalence of ureaplasma urealyticum and mycoplasma hominis in women with chronic urinary symptoms. Urology 74(1):62–66CrossRefPubMed

29.

Kim H‑J (2016) Update on the pathology and diagnosis of interstitial cystitis/bladder pain syndrome: a review. Int Neurourol J 20(1):13–17CrossRefPubMedPubMedCentral

30.

Regauer S (2016) Mast cell activation syndrome in pain syndromes bladder pain syndrome/interstitial cystitis and vulvodynia. Transl Androl Urol 5(3):396–397CrossRefPubMedPubMedCentral

31.

Gamper M, Regauer S, Welter J et al (2015) Are mast cells still good biomarkers for bladder pain syndrome/interstitial cystitis? J Urol 193(6):1994–2000CrossRefPubMed

32.

Tettamanti G, Nyman-Iliadou A, Pedersen NL et al (2011) Influence of smoking, coffee, and tea consumption on bladder pain syndrome in female twins. Urology 77(6):1313–1317CrossRefPubMedPubMedCentral

33.

Parsons CL, Koprowski PF (1991) Interstitial cystitis: successful management by increasing urinary voiding intervals. Urology 37(3):207–212CrossRefPubMed

34.

Hill JR, Isom-Batz G, Panagopoulos G et al (2008) Patient perceived outcomes of treatments used for interstitial cystitis. Urology 71(1):62–66CrossRefPubMed

35.

Nickel JC, Herschorn S, Whitmore KE et al (2015) Pentosan polysulfate sodium for treatment of interstitial cystitis/bladder pain syndrome: insights from a randomized, double-blind, placebo controlled study. J Urol 193(3):857–862CrossRefPubMed

36.

Nickel JC, Barkin J, Forrest J et al (2005) Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis. Urology 65(4):654–658CrossRefPubMed

37.

Cervigni M (2015) Interstitial cystitis/bladder pain syndrome and glycosaminoglycans replacement therapy. Transl Androl Urol 4(6):638–642PubMedPubMedCentral

38.

Moldwin RM, Evans RJ, Stanford EJ et al (2007) Rational approaches to the treatment of patients with interstitial cystitis. Urology 69(4 Suppl):73–81CrossRefPubMed

39.

Davis EL, El Khoudary SR, Talbott EO et al (2008) Safety and efficacy of the use of intravesical and oral pentosan polysulfate sodium for interstitial cystitis: a randomized double-blind clinical trial. J Urol 179(1):177–185CrossRefPubMed

40.

van Ophoven A, Hertle L (2005) Long-term results of amitriptyline treatment for interstitial cystitis. J Urol 174(5):1837–1840CrossRefPubMed

41.

Chen H, Wang F, Chen W et al (2014) Efficacy of daily low-dose sildenafil for treating interstitial cystitis: results of a randomized, double-blind, placebo-controlled trial – treatment of interstitial cystitis/painful bladder syndrome with low-dose sildenafil. Urology 84(1):51–56CrossRefPubMed

42.

Sairanen J, Tammela TLJ, Leppilahti M et al (2005) Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study. J Urol 174(6):2235–2238CrossRefPubMed

43.

Nickel JC, Egerdie RB, Steinhoff G et al (2010) A multicenter, randomized, double-blind, parallel group pilot evaluation of the efficacy and safety of intravesical sodium chondroitin sulfate versus vehicle control in patients with interstitial cystitis/painful bladder syndrome. Urology 76(4):804–809CrossRefPubMed

44.

Parsons CL, Koziol JA, Proctor JG et al (2015) Heparin and alkalinized lidocaine versus alkalinized lidocaine for treatment of interstitial cystitis symptoms. Can J Urol 22(2):7739–7744PubMed

45.

Henry RA, Morales A, Cahill CM (2015) Beyond a simple anesthetic effect: Lidocaine in the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. Urology 85(5):1025–1033CrossRefPubMed

46.

Nomiya A, Naruse T, Niimi A et al (2013) On- and post-treatment symptom relief by repeated instillations of heparin and alkalized lidocaine in interstitial cystitis. Int J Urol 20(11):1118–1122CrossRefPubMed

47.

Downey A (2015) Intravesical chondroitin sulphate for interstitial cystitis/painful bladder syndrome. Ulster Med J 84(3):161–163PubMedPubMedCentral

48.

Tomoe H (2015) In what type of interstitial cystitis/bladder pain syndrome is DMSO intravesical instillation therapy effective? Transl Androl Urol 4(6):600–604PubMedPubMedCentral

49.

Cervigni M, Sommariva M, Tenaglia R et al (2016) A randomized, open-label, multicenter study of the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate versus dimethyl sulfoxide in women with bladder pain syndrome/interstitial cystitis. Neurourol Urodyn. doi:10.1002/nau.23091

50.

Payne CK, Mosbaugh PG, Forrest JB et al (2005) Intravesical resiniferatoxin for the treatment of interstitial cystitis: a randomized, double-blind, placebo controlled trial. J Urol 173(5):1590–1594CrossRefPubMed

51.

Neuhaus J, Schwalenberg T (2012) Intravesical treatments of bladder pain syndrome/interstitial cystitis. Nat Rev Urol 9(12):707–720CrossRefPubMed

52.

van Ophoven A, Rossbach G, Pajonk F et al (2006) Safety and efficacy of hyperbaric oxygen therapy for the treatment of interstitial cystitis: a randomized, sham controlled, double-blind trial. J Urol 176(4 Pt 1):1442–1446CrossRefPubMed

53.

Lucioni A, Bales GT, Lotan TL et al (2008) Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int 101(3):366–370CrossRefPubMed

54.

Meng J, Wang J, Lawrence G et al (2007) Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci 120(Pt 16):2864–2874CrossRefPubMed

55.

Chuang Y‑C, Yoshimura N, Huang C‑C et al (2009) Intravesical botulinum toxin A administration inhibits COX-2 and EP4 expression and suppresses bladder hyperactivity in cyclophosphamide-induced cystitis in rats. Eur Urol 56(1):159–166CrossRefPubMed

56.

Jhang J‑F, Kuo H‑C (2016) Botulinum toxin A and lower urinary tract dysfunction: pathophysiology and mechanisms of action. Toxins (Basel) 8(4):120CrossRef

57.

Kuo H‑C, Jiang Y‑H, Tsai Y‑C et al (2016) Intravesical botulinum toxin – A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment – A prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. Neurourol Urodyn 35(5):609–614CrossRefPubMed

58.

Lee C‑L, Kuo H‑C (2013) Intravesical botulinum toxin a injections do not benefit patients with ulcer type interstitial cystitis. Pain Physician 16(2):109–116PubMed

59.

Steinberg AC, Oyama IA, Whitmore KE (2007) Bilateral S3 stimulator in patients with interstitial cystitis. Urology 69(3):441–443CrossRefPubMed

60.

Whitmore KE, Payne CK, Diokno AC et al (2003) Sacral neuromodulation in patients with interstitial cystitis: a multicenter clinical trial. Int Urogynecol J Pelvic Floor Dysfunct 14(5):305–309CrossRefPubMed

61.

Marinkovic SP, Gillen LM, Marinkovic CM (2011) Minimum 6‑year outcomes for interstitial cystitis treated with sacral neuromodulation. Int Urogynecol J 22(4):407–412CrossRefPubMed

62.

Powell CR, Kreder KJ (2010) Long-term outcomes of urgency-frequency syndrome due to painful bladder syndrome treated with sacral neuromodulation and analysis of failures. J Urol 183(1):173–176CrossRefPubMed

63.

Payne RA, O’Connor RC, Kressin M et al (2009) Endoscopic ablation of Hunner’s lesions in interstitial cystitis patients. Can Urol Assoc J 3(6):473–477CrossRefPubMedPubMedCentral

64.

Linn J, Hohenfellner M, Roth S et al (1998) Treatment of interstitial cystitis. Comparison of subtrigonal and supratrigonal cystectomy combined with orthotopic bladder substitution. J Urol 159(3):774–778CrossRefPubMed

65.

Peeker R, Aldenborg F, Fall M (1998) The treatment of interstitial cystitis with supratrigonal cystectomy and ileocystoplasty: difference in outcome between classic and nonulcer disease. J Urol 159(5):1479–1482CrossRefPubMed

66.

Yang T‑X, Luo D‑Y, Li H et al (2016) Is urethrectomy necessary during cystectomy in patients with interstitial cystitis or bladder pain syndrome? Urology. doi:10.1016/j.urology.2016.07.003

67.

van Ophoven A, Oberpenning F, Hertle L (2002) Long-term results of trigone-preserving orthotopic substitution enterocystoplasty for interstitial cystitis. J Urol 167(2 Pt 1):603–607CrossRefPubMed

68.

Kochakarn W, Lertsithichai P, Pummangura W (2007) Bladder substitution by ileal neobladder for women with interstitial cystitis. Int Braz J Urol 33(4):486–492CrossRefPubMed

69.

Kim HJ, Lee JS, Cho WJ et al (2014) Efficacy and safety of augmentation ileocystoplasty combined with supratrigonal cystectomy for the treatment of refractory bladder pain syndrome/interstitial cystitis with Hunner’s lesion. Int J Urol 21(Suppl 1):69–73CrossRefPubMed

70.

Braundmeier-Fleming A, Russell NT, Yang W et al (2016) Stool-based biomarkers of interstitial cystitis/bladder pain syndrome. Sci Rep 6:26083CrossRefPubMedPubMedCentral

71.

Peters KM, Hasenau D, Killinger KA et al (2014) Liposomal bladder instillations for IC/BPS: an open-label clinical evaluation. Int Urol Nephrol 46(12):2291–2295CrossRefPubMedPubMedCentral

72.

Kim A, Shin D‑M, Choo M‑S (2016) Stem cell therapy for interstitial cystitis/bladder pain syndrome. Curr Urol Rep 17(1):1CrossRefPubMed

73.

Neuhaus J, Schulte-Baukloh H, Stolzenburg J‑U et al (2012) Individual receptor profiling as a novel tool to support diagnosis of bladder pain syndrome/interstitial cystitis (BPS/IC). World J Urol 30(5):693–700CrossRefPubMed

Titel: Interstitielle Zystitis
Diagnostik, medikamentöse und operative Therapie
verfasst von: Dr. A. Gonsior
J. Neuhaus
L. C. Horn
Prof. T. Bschleipfer
J.-U. Stolzenburg
Publikationsdatum: 24.05.2017
Verlag: Springer Medizin
Schlagwörter: Schmerzsyndrome
Zystitis
Zystektomie
Zystitis
Erschienen in: Die Urologie / Ausgabe 6/2017
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI: https://doi.org/10.1007/s00120-017-0408-2

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2017

Prostatastanzbiopsie: So lassen sich Infektionen vermeiden

Die GeSRU auf den deutschen urologischen Regionalkongressen 2017

Ein ungewöhnlicher Nierentumor – hätten Sie es gewusst?

Funktionsstörungen des unteren Harntrakts nach Rückenmarkschädigung

Neue mikrobiologische Techniken

Nivolumab in Kombination mit Ipilimumab vs. Sunitinib-Monotherapie – SUNNIFORECAST – AN 41/16 der AUO